Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype

Free Radical Biology and Medicine

Volumn 27, Issue 5-6, 1999, Pages 544-553

  Ramassamy, Charles ^a   Averill, Diana ^b   Beffert, Uwe ^c   Bastianetto, Stephane ^a   Theroux, Louise ^a   Lussier Cacan, Suzanne ^d   Cohn, Jeffrey S ^d   Christen, Yves ^e   Davignon, Jean ^d   Quirion, Rémi ^a,f   Poirier, Judes ^a,f  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^e IPSEN   (France)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Apolipoprotein E concentration; Catalase; DHEA; Free radicals; Ginkgo biloba extract EGb 761; Glutathione; Glutathione Peroxidase; Lipid peroxidation

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN E; CATALASE; GINKGO BILOBA EXTRACT; GLUTATHIONE; GLUTATHIONE PEROXIDASE; PRASTERONE; RECOMBINANT PROTEIN; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FRONTAL CORTEX; GENOTYPE; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; ANTIOXIDANTS; APOLIPOPROTEINS E; BRAIN; DEHYDROEPIANDROSTERONE; FEMALE; FLAVONOIDS; FREE RADICAL SCAVENGERS; GENOTYPE; GINKGO BILOBA; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; HYDROGEN PEROXIDE; IRON; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; RECOMBINANT PROTEINS;

GINKGO BILOBA;

EID: 0032817968     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(99)00102-1     Document Type: Article

References (62)

1. Chartier-Harlin M.-C., Crawford F., Houlden H., Warren A., Hughes D., Fidani L., Goate A., Rossor M., Roques P., Hardy J., Mullan M. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature. 353:1991;844-846.
2. Citron M., Oltersorf T., Haas C., McColongue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., Selkoe D.J. Mutations of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 360:1992;672-674.
3. Corder E.H., Saunders A.M., Strittmater W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E. type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
4. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 342:1993;697-699.
5. Strittmater W.J., Saunders D.E., Schemchel M.A., Pericak-Vance J., Enghild G.S., Roses A.D. Apolipoprotein E high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease . Proc. Natl. Acad. Sci. USA. 90:1993;1977-1981.
6. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingel W.J., Yu C.E., Jondro P.D., Schmidt S.D., Wang K., Crowley A.C., Fu Y.H., Guenette S.Y., Galas D., Nemens E., Wijsman E.M., Bird T.D., Schellenberg G.D., Tanzi R.E. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 269:1995;973-977.
7. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque-Foncin G., Bruni M.P., Montesi M.P., Sorbi S., Rainero I., Pinessi I., Nee L., Chumakov I., Pollen D., Brookes A., Sanseau P., Polinsky R.J., Wasco W., Da Silva H.A.R., Haines J.L., Perick-Vance M.A., Tanzi R.E., Roses A.D., Fraser P.E., Rommens J.M., St. George-Hyslop P.H. Cloning of a gene bearing missence mutations in early-onset familial Alzheimer's disease. Nature. 375:1995;754-760.
8. Utterman G., Langenbeck U., Beisiegel U., Weber W. Genetics of the apolipoprotein E system in man. Am. J. Hum. Genet. 32:1980;339-347.
9. Rall S.C., Weisgraber K.H., Mahley R.W. Human apolipoprotein E. The complete amino acid sequence. J. Biol. Chem. 257:1982;4171-4178.
10. Weisgraber K.H., Innerarity T.L., Mahley R.W. Abnormal lipoprotein receptor-binding activity of the human E apolipoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257:1982;2518-2521.
11. Strittmatter W.J., Saunders A.M., Goedert M., Weisgraber K.H., Dong L.M., Jakes R., Huang D.Y., Pericak-Vance M.A., Schmechel D., Roses A.D. Isoform specific interactions of apolipoprotein E with microtubule-associated protein tau implications for Alzheimer's disease . Proc. Natl. Acad. Sci. USA. 91:1994;11183-11186.
12. Beffert U., Aumont N., Dea D., Lussier-Cacan S., Davignon J., Poirier J. Beta-amyloid peptides increases the binding and internalization of apolipoprotein E to hippocampal neurons. J. Neurochem. 70:1998;1458-1466.
13. Jordan J., Galindo M.F., Miller R.J., Reardon C.A., Getz G.S., LaDu M.J. Isoform effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J. Neurosci. 18:1998;1-10.
14. Poirier J. Apolipoprotein E in animal model of CNS injury and in Alzheimer's disease. Trends Neurosci. 17:1994;525-530.
15. Igbavboa U., Avdulov N.A., Chochina S.V., Wood W.G. Transbilayer distribution of cholesterol is modified in brain synaptic plasma membranes of knockout mice deficient in the low-density lipoprotein receptor, apolipoprotein E, or both proteins. J. Neurochem. 69:1997;1661-1667.
16. Miyata M., Smith J. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity insults and β-amyloid peptides. Nature Genet. 14:1996;55-61.
17. Hayek T., Oiknine J., Brook J.G., Aviram M. Increased plasma and lipoprotein and lipid peroxidation in APOE-deficient mice. Biochem. Biophys. Res. Commun. 201:1994;1567-1574.
18. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23:1997;134-147.
19. Subbarao K.V., Richardson J.S., Ang L.C. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J. Neurochem. 55:1990;342-345.
20. Balazs L., Leon M. Evidence of anoxidative challenge in the Alzheimer's brain. Neurochem. Res. 19:1994;1131-1137.
21. Yan S.D., Chen X., Schmidt A.M., Brett J., Godman G., Zou Y.S., Scott C.W., Caputo C., Frappier T., Smith M.A., Perry G., Yen S.H., Stern D. Glycated tau protein in Alzheimer's disease a mechanism for induction of oxidant stress . Proc. Natl. Acad. Sci. USA. 91:1994;7787-7791.
22. Lovell M.A., Ehmann W.D., Butler S.M., Markesbery W.R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 45:1995;1594-1601.
23. Sayre L.M., Zelasko D.A., Harris P.L.R., Perry G., Salomom R.G., Smith M.A. 4-HNE-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68:1997;2092-2097.
24. Smith M.A., Taneda S., Richey P.L., Miyata S., Yan S.D., Stern D., Sayre L.M., Monnier V.M., Perry G. Advanced Maillard reaction end products are associated with Alzheimer's disease pathology. Proc. Natl. Acad. Sci. USA. 91:1994;5710-5714.
25. Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., Manogue K., Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 91:1994;4766-4770.
26. Smith M.A., Sayre L.M., Anderson V.E., Beal M.F., Kowall N., Richey P.L., Perry G. Oxidative damage in Alzheimer's disease. Nature. 382:1996;120-121.
27. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell. 77:1994;817-827.
28. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., Floyd R.A., Butterfield D.A. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide relevance to Alzheimer disease . Proc. Natl. Acad. Sci. USA. 91:1994;3270-3274.
29. Loeffler D.A., Connor J.R., Juneau P.L., Snyder B.S., Kanaley L., DeMaggio A.J., Nguyen H., Brickman C.M., Lewitt P.A. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J. Neurochem. 65:1995;710-716.
30. Zhou Y., Richardson J.S., Mombourquette M.J., Weil J.A. Free radical formation in autopsy samples of Alzheimer and control cortex. Neurosci. Lett. 195:1995;89-92.
31. Khachaturian K. Diagnosis of Alzheimer's disease. Arch. Neurol. 42:1985;1097-1105.
32. Cohn J.S., Tremblay M., Amiot M., Bouthillier D., Roy M., Genest J., Davignon J. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 16:1996;149-159.
33. Okhawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95:1979;351-358.
34. Brown R.E., Jarvis K.L., Hyland K.J. Protein measurement using bicinchoninic acid elimination of interfering substances . Anal. Biochem. 189:1989;136-139.
35. Aebi H. Catalase in vitro. Methods Enzymol. 105:1984;121-126.
36. Paglia D.E., Valentine W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 70:1967;158-169.
37. Anderson M.E. Greenwald R.A. Handbook of methods for oxygen radical research. 1989;317-323 CRC Press, Boca Raton, FL.
38. Mahley R.W., Innerarity T.L., Rall S.C., Weisgraber K.H. Lipoprotein receptors and cholesterol homeostasis. Biochim. Biophys. Acta. 737:1983;197-222.
39. Mahley R.W. Apolipoprotein E cholesterol transport protein with expanding role in cell biology . Science. 240:1988;622-630.
40. Bertrand P., Poirier J., Oda T., Finch C.E., Pasinetti G.M. Association of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer's disease. Brain Res. 33:1995;174-178.
41. Lyras L., Cairns N.J., Jenner A., Jenner P., Halliwell B. An assessment of oxidative damage to proteins, lipids and DNA in brain from patients with Alzheimer's disease. J. Neurochem. 68:1997;2061-2069.
42. Marcus D.L., Thomas C.L., Rodriguez C., Simberkoff K., Tsai J.S., Strafaci J.A., Freedman M.L. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp. Neurol. 150:1998;40-44.
43. Montine K.S., Kim P.J., Olson S.J., Markesbery W.R., Montine T.J. 4-hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J. Neuropath. Exp. Neurol. 56:1997;866-871.
44. Montine K.S., Olson S.J., Amarnath V., Whetsell W.O., Graham D.G., Montine T. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am. J. Pathol. 150:1997;437-443.
45. Namekata K., Imagawa M., Terashi A., Ohta S., Oyama F., Ihara Y. Association of transferrin C2 allele with late-onset Alzheimer's disease. Hum. Genet. 101:1997;126-129.
46. Smith M.A., Harris P.L.R., Sayre L.M., Perry G. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA. 94:1997;9866-9868.
47. Hunt C.R., Sim J.E., Sullivan S.J., Featherstone T., Golden W., Von Kapp-Herr C., Hoch R.A., Gomez R.A., Parsian A.J., Spitz D.R. Genomic instability and catalase gene amplification induced by chronic exposure to oxidative stress. Cancer Res. 58:1998;3986-3992.
48. Gsell W., Conard R., Hickethier M., Sofic E., Frolich L., Wichart I., Jellinger K., Moll G., Ransmayer G., Beckman H., Riederer P. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer's type. J. Neurochem. 64:1995;1216-1223.
49. Palmer A.M., Burns M.A. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res. 645:1994;338-342.
50. Hayn M., Kremser K., Singewald N., Cairns N., Nemethova M., Lubec B., Lubec G. Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down's syndrome and Alzheimer's disease. Life Sci. 59:1996;537-544.
51. Carcelain G., Davis F., Lepage S., Bonnefront-Rousselot D., Delattre J., Legrand A., Peynet J., Troupel S. Simple method for quantifying alpha-tocopherol in low-density lipoproteins and in high-density lipoproteins. Clin. Chem. 38:1992;1792-1795.
52. Harr S.D., Uint R., Hollister B.T., Hyman B.T., Mendez A.J. Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J. Neurochem. 66:1996;2429-2435.
53. Lehtimaki T., Pirttila T., Mehta P.D., Wisniewski M., Frey H., Nikkari T. Apolipoprotein E (APOE) polymorphism and its influence on apoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum. Genet. 95:1995;39-42.
54. Hahne S., Nordstedt C., Ahlin A., Nyback H. Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls. Neurosci. Lett. 224:1997;99-102.
55. LeBars P.L., Katz M.M., Berman N., Itil T.M., Freedman A.M., Schatzberg A.F. A placebo-controlled, double blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA. 278:1997;1327-1333.
56. Maurer K., Ihl R., Dierks T., Frolich L. Clinical efficacy of Ginkgo biloba specila extract EGb 761 in dementia of the Alzheimer type. J. Psychiat. Res. 31:1997;645-655.
57. Roberts E., Bologa L., Flood J.F., Smith G.E. Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice. Brain Res. 406:1987;357-362.
58. Drieu K. Preparation and definition of Ginkgo biloba extract. Presse Med. 15:1986;1455-1457.
59. Robel, P.; Beaulieu, E. E. Neurosteroids: biosynthesis and function. Critical Review in Neurobiology 9:383-394; 1995.
60. Longcope C. Dehydroepiandrosterone metabolism. J. Endocrinol. 150:1996;S125-S127.
61. Poirier J., Delisle M.C., Quirion R., Aubert I., Farlow M., Lahiri D., Hui S., Bertrand P., Nalbantoglu J., Gilfix B.M., Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 92:1995;12260-12264.
62. Richard F., Helbecque N., Neuman E., Guez D., Levy R., Amouyel P. APOE genotyping and response to drug treatment in Alzheimer's disease. Lancet. 349:1997;539.